Aarti Drugs Ltd

Aarti Drugs Management Change

Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.

Aarti Drugs Investor Presentation: Key Takeaways

Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.

Aarti Drugs Annual General Meeting

Aarti Drugs Limited conducted its 41st Annual General Meeting on September 26, 2026, to consider various ordinary and special business resolutions.

Aarti Drugs Annual General Meeting

Aarti Drugs Ltd has issued a notice for its 41st Annual General Meeting scheduled for September 26, 2026. The agenda includes financial statements and director appointments.

Aarti Drugs Annual Report

Aarti Drugs has released its Annual Report for FY 2025-26 and notice for its 41st Annual General Meeting scheduled for September 26, 2026.

Aarti Drugs Employee Stock Options

Aarti Drugs Limited board approved the Performance Stock Option Plan 2026. The plan involves granting up to 8,00,000 stock options to eligible employees, subject to shareholder approval.

Aarti Drugs Board Meeting Date

Aarti Drugs Ltd scheduled a Board Meeting on August 27, 2026, to consider the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'.

Aarti Drugs Other Announcement

Aarti Drugs Ltd has submitted its quarterly shareholding pattern in compliance with Regulation 31(1)(b) of SEBI (LODR) Regulations for the quarter ended June 30, 2026.

Aarti Drugs Legal & Regulatory

Aarti Drugs disclosed that the Supreme Court dismissed the GST Department's Special Leave Petition, effectively disposing of the tax litigation matter in the company's favor.

Value

₹230.7 Cr

Aarti Drugs Legal & Regulatory

The Supreme Court dismissed the GST Department's Special Leave Petition, favoring the company. This favorable order resolves the pending tax litigation regarding GST demands.

Aarti Drugs Investor Presentation: Key Takeaways

Aarti Drugs reported Q1 FY27 revenue of ₹703.6 Cr, up 19% YoY, with EBITDA rising 30% to ₹96.9 Cr. Strategy focuses on backward integration at Sayakha and USFDA-regulated market expansion.

Aarti Drugs Investor Presentation: Key Takeaways

Aarti Drugs reported Q1FY27 revenue of ₹703.6 Cr with 19% YoY growth. EBITDA rose 30% to ₹96.9 Cr, driven by volume growth and improved pricing realizations across API and Specialty Chemicals portfolios.

Aarti Drugs Results Update

Aarti Drugs reported Q1 FY27 consolidated revenue of ₹703.6 crore and EBITDA of ₹96.9 crore, reflecting 19% and 30% YoY growth respectively.

Aarti Drugs Legal & Regulatory

Aarti Drugs Limited received a revocation order from the GPCB for its Sayakha plant, allowing continued operations. The company paid Rs. 0.102 Crore as interim compensation.

Value

₹0.10 Cr

Aarti Drugs Board Meeting Outcome

Aarti Drugs announced significant board changes, including the appointment of new Executive Directors, several re-appointments, and the resignation of directors Prakash M. Patil and Uday M. Patil.

Aarti Drugs Management Change

Aarti Drugs Limited announced the retirement of MD & CEO Prakash M. Patil. The company appointed Rashesh C. Gogri as Chairman and Adhish P. Patil as Managing Director.

Aarti Drugs Q1 FY27 Results: Net Profit ₹50.1 Cr, Down 7.2% YoY

Aarti Drugs Ltd reported revenue from operations of ₹702.8 Cr (+19.0% YoY) and net profit of ₹50.1 Cr (-7.2% YoY) for Q1 FY27.

Key figure

Net profit ₹50.1 Cr · -7.2% YoY

Aarti Drugs Board Meeting Date

Aarti Drugs Limited has scheduled a board meeting for July 31, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.

Aarti Drugs Other Announcement

Aarti Drugs Ltd has filed its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI regulations.

Aarti Drugs Adverse Business Impact

Aarti Drugs received a closure directive from GPCB for its Saykha manufacturing unit due to alleged non-compliances. The company is taking corrective measures for revocation.